Khiron Life Sciences Announces Mexican Retail Distribution for Kuida® CBD Cosmeceutical Brand

Khiron Life Sciences Announces Mexican Retail Distribution for Kuida® CBD Cosmeceutical Brand

Khiron Life Sciences Corp. (TSXV: KHRN), (OTCQB: KHRNF), an integrated medical cannabis company with its core operations in Colombia, announced today that the Company has expanded an agreement with Farmalisto, the regions leading digital pharmacy, to market and distribute the Company’s Kuida® CBD cosmeceutical brand to a population of over 120 million consumers in Mexico, subject to approvals from the Federal Commission for the Protection of Health Risks (COFEPRIS).

Kuida®, the first consumer brand of Khiron’s Wellness unit, brings the benefits of cannabidol (CBD) to a comprehensive portfolio of body and skin care products for women. Launched in Colombia in September 2018 via retail, wholesale and online channels, Kuida® will now be available in Mexico, a significant market segment with a population of over 120 Million. Mexico is among the top 10 markets in the world for cosmetics and personal care products (US Department of Commerce), and the second biggest market for beauty products in Latin America.

Alvaro Torres, Khiron Co-founder and CEO stated,”Mexico is a priority market for Kuida®, where we see tremendous fascination with new innovations in the beauty care market. Included in our previously announced business strategy to enter the Mexican market, extending our supply deal with Farmalisto enables us to leverage their e-commerce capabilities and network to connect more women in Mexico with the Kuida® brand.”

Farmalisto is one of Latin America’s leading digital drugstores with over one million yearly visits, sustained annual sales growth of 150%, and a strong presence in Mexico. Led by CEO and Co-founder Joaquin Mora, Farmalisto supplies customers with innovative products, delivered with leading commercial technology, provided through the most innovative digital platform. To see Kuida®  on Farmalisto see:

José Joaquin Mora, CEO & Co-founder of Farmalisto stated,”Farmalisto is the biggest and most comprehensive digital health service platform in Mexico. As a pioneer in the pharmaceutical e-commerce space we’re redefining the pharmacy, creating a simpler, easier and lower cost way of prescribing drugs and health services, at any time, anywhere. With one million monthly visits and 500,000 orders delivered so far we are the fastest growing these e-commerce platform in Latin America.”

Source: Mexican Secretariat of Economy (SE), Mexican Internet Trade Data System (SIAVI).

Khiron Life Sciences Corp.  (TSXV: KRHN, OTCQB: KHRNF, Frankfurt: A2JMZC) (“Khiron” or the”Company”) is positioned to be the dominant integrated medical cannabis business in Latin America. Khiron has core operations in Colombia and is fully licensed in the country for the cultivation, production, domestic distribution, and global export of both tetrahydrocannabinol (THC) and cannabidiol (CBD) medical cannabis. In May 2018, Khiron listed on the TSX Venture Exchange, becoming among the first Colombian based medical cannabis organizations to trade on any exchange globally.

With a focused regional strategy and individual oriented approach, the business combines global scientific expertise, agricultural benefits, branded product market entry experience and education to induce prescription and brand loyalty to address priority medical conditions such as chronic pain, epilepsy, depression and stress from the Latin American market of over 620 million people. Khiron is directed by Co-founder and Chief Executive Officer, Alvaro Torres, together with an experienced executive team, and a knowledgeable Board of Directors that includes former President of Mexico, Vicente Fox.

Further information on Khiron Life Sciences can be found at

Forward-Looking Statements

This media release may contain certain forward-looking information and statements (“forward-looking information”) within the meaning of applicable Canadian securities laws, which are not based on historical fact, including without limitation statements containing the words”believes”,”expects”,”plans”,”intends”,”will”,”should”,”expects”,”continue”,”estimate”,”forecasts” and other similar expressions. Readers are cautioned to not place undue reliance on forward-looking info. Actual results and developments may differ materially from those contemplated by these statements. Khiron undertakes no obligation to remark analyses, expectations or statements made by third-parties in respect of Khiron, its securities, or financial or operating results (as applicable). Although Khiron believes that the expectations reflected in forward-looking information in this press release are reasonable, such forward-looking information was based on expectations, assumptions and factors concerning future events which may prove to be inaccurate and are subject to numerous risks and uncertainties, certain of which are beyond Khiron’s management, including the risk factors discussed in Khiron’s Filing Statement which can be found on Khiron’s SEDAR profile at The forward-looking information included in this press release is expressly qualified by this cautionary statement and are made as of the date hereof.

Released at Tue, 06 Nov 2018 12:08:45 +0000

Posted in: Investing

Comments are closed.